), the leading innovator and provider of glyconutrient technology and naturally-sourced supplements based on
Real Food Technology®
solutions, and founders of the Mission 5 Million
social entrepreneurial movement, announced the issuance of five new patents to date in 2013 for technologies related to its product portfolio. In total, Mannatech now holds 90 patents worldwide.
In 2013, four patents for the technology related to Mannatech’s Ambrotose AO
formulation have been issued in various countries (two in Mexico, one in Canada and one in Taiwan), and one patent has been issued in Australia for the technology related to its GI-ProBalance
Ambrotose AO capsules
combine a blend of plant extracts and antioxidant compounds that are clinically proven to provide over 2 ½ times more antioxidant protection than five servings of fruits and vegetables.
are Mannatech’s solution for superior probiotic health, providing six different strains of probiotics and two different prebiotics for a wide variety of health support.
“Mannatech’s patent portfolio, which the company had the foresight to start developing in the mid-1990s, has now yielded 90 patents issued globally,” said Dr. Robert A. Sinnott, CEO and Chief Science Officer of Mannatech. “Our chain of systematic research and intellectual property development has continued without pause throughout the entire history of the company. This gives us much more protected space in the rapidly growing wellness industry than almost all of our competitors have, or ever will obtain. This is a huge asset in an industry that has significantly raised the bar on validation of health supplements.”
Individuals interested in Mannatech’s products, or exploring its social entrepreneurial efforts to help fight global malnutrition, can learn more at
Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. Mannatech is dedicated to its platform of Social Entrepreneurship based on the foundation of promoting, aiding and optimizing nutrition where it is needed most around the world. Mannatech’s proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech Republic, the Republic of Korea, Mexico, Namibia, Hong Kong and Ukraine. For more information, visit
Please note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “believe,” “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain Associates and Members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.